|
|
|
|
|
Join our live expert webinar
|
|
|
Immune Checkpoint Inhibitors in First-line Treatment of Metastatic NSCLC
|
|
|
Monday, December 20, 2021 • 11:00AM ET
|
|
|
Expert insights provided by:
|
|
|
Hossein Borghaei, DO, MS
Chief, Division of Thoracic Medical Oncology
Professor, Department of Hematology/Oncology
Co-Director, Immune Monitoring Facility
Gloria and Edmund M. Dunn Chair in Thoracic Oncology
Fox Chase Cancer Center
Philadelphia, PA |
|
|
|
Prof. Dr. Martin Reck
Head of Department Thoracic Oncology
Head of Clinical Trial Department
LungenClinic Grosshansdorf
Germany |
|
|
|
Objectives:
- Gain insights into factors guiding treatment selection in non-small cell lung cancer (NSCLC) lacking actionable genetic alterations
- Review safety and efficacy data of immune checkpoint inhibitors in first-line treatment of metastatic NSCLC
- Discuss treatment decision-making based on PD-L1 expression levels in NSCLC
|
|
|
|
|
|
|
|
|
|
